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Summary: VȖ9Vδβ T-cells with APC-like phenotype can be found in vivo in P. 
falciparum-infected patients. VȖ9Vδβ T-cells stimulated in vitro with P. falciparum-
infected red blood cell acquire an APC-like phenotype, induce naïve αȕ T-cell 
activation and perform antigen cross-presentation. 
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ABSTRACT  
During Plasmodium falciparum infections, erythrocyte-stage parasites inhibit dendritic 
cell maturation and function; compromising development of effective anti-malarial 
adaptive immunity. Human VȖ9Vδβ T-cells can act in vitro as APCs and induce αȕ T-
cell activation. However, the relevance of this activity in pathophysiological contexts 
in vivo has remained elusive. Since VȖ9Vδβ T-cells are activated during the early 
immune response against P.falciparum infection, we investigated whether they could 
contribute to the instruction of adaptive immune responses toward malaria parasites. 
In P.falciparum-infected patients, VȖ9Vδβ T-cells presented an increased surface 
expression of APC-associated markers HLA-DR and CD86. In response to infected 
red blood cells in vitro, VȖ9Vδβ T-cells readily up-regulated surface expression of 
HLA-DR, HLA-ABC, CD40, CD80, CD83 and CD86, induced naive αȕ T-cell 
responses, and cross-presented soluble prototypical protein to antigen-specific CD8+ 
T-cells. Our findings indicate that P. falciparum parasites induce genuine APC 
properties in VȖ9Vδβ T-cells and qualify this subset as an alternative professional 
APC in malaria patients, which could be harnessed for therapeutic interventions and 
vaccine design. 
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INTRODUCTION  
Accumulating evidence has shown that a non-conventional T-cell, the Ȗδ T-cell, is 
involved in the early immune response to erythrocyte stage infection of Plasmodium 
spp. malaria parasites, including P.falciparum and P.vivax. A subset unique to 
primates and expressing the VȖ9Vδβ T-cell receptor (TCR) is activated in a major 
histocompatibility complex (MHC)-independent manner by small non-peptidic 
phosphorylated molecules commonly referred to as phosphoantigens. The most 
potent phosphoantigen is HMBPP (4-hydroxy-3-methyl-but-2-enyl diphosphate), 
produced by the non-mevalonate isoprenoid pathway used by numerous 
microorganisms, including Apicomplexan parasites such as Plasmodium spp. 
(reviewed[1]). In vivo, human blood V9V2 T-cells are activated and expand during 
primary P.falciparum infection [2, 3]. In vitro, it has been shown that VȖ9Vδβ T-cells 
inhibit erythrocyte stage proliferation [4] by granulysin release targeting the 
extracellular invasive parasite form (merozoites) [2, 3]. Granulysin levels are elevated 
in malaria patients and correlate with the percentage of CD3-positive T-cells 
expressing Vδβ [2] consistent with substantial degranulation of V9V2 T-cells during 
P.falciparum infection. 
In addition to a cytotoxic role, it has been proposed that VȖ9Vδβ T-cells can mimic in 
part dendritic cell (DC) function and license primary  T-cell responses. VȖ9Vδβ T-
cells stimulated in vitro by synthetic phosphoantigens, express antigen presenting 
cell (APC) phenotype and display a DC-like morphology. They are able to present 
both viral and bacterial antigens to CD4+  T-cells and can even cross-present 
antigens to CD8+  T-cells [5-10]. However, their APC potential in response to an 
infectious agent in vivo has yet to be demonstrated. It is possible that VȖ9Vδβ T-cells 
represent an alternative route of antigen presentation during the immune response 
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that follows P.falciparum infection. This question is particularly relevant as there is 
both in vitro and ex vivo evidence that Plasmodium erythrocyte stage parasites inhibit 
effective DC maturation and function [11-15].  
We therefore investigated the antigen presenting ability of VȖ9Vδβ T-cells after 
exposure to erythrocyte stage P.falciparum parasites (iRBC), looking at both their 
phenotype and function. We found that in vivo there is an increase in surface 
expression of APC-associated makers on blood VȖ9Vδβ T-cells from P. falciparum-
infected patients. In vitro, VȖ9Vδβ T-cells up-regulated surface expression of a range 
of APC-markers in response to iRBC, and exhibited functions of professional APCs in 
mixed lymphocyte reactions and a cross-presentation assay. To our knowledge, this 
is the first demonstration of an APC activity of VȖ9Vδβ T-cells in an infectious 
context, and has implications for therapeutic interventions and improved vaccine 
design.  
 
MATERIALS AND METHODS  
Clinical samples 
Clinical blood samples were collected from P.falciparum-infected patients admitted to 
the University Hospital of Bordeaux on admission prior to treatment (day 0) and, for 
those who came back for a medical follow-up, 7 days after treatment (day 7). Non-
malaria febrile control samples were collected as were malaria-samples from patients 
presenting with high-grade fever and a record of travel to malaria endemic zones, but 
for whom malaria attack was excluded. Healthy donors from the blood bank 
(Etablissement Français du Sang, EFS-Aquitaine) were processed as healthy 
controls. Malaria patients were classified as described in the text according to [16, 
17]. Severe malaria was defined as described [18]. All patients gave informed 
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consent. The ethical agreement obtained for this study was restricted to leftovers 
from the blood samples used for diagnosis, corresponding to approximately 0.5-1 ml 
of blood.  
APC phenotyping by flow cytometry 
For ex vivo analysis, 300 µl whole blood was labelled with anti-CD3-BV510, 
CD45RA-PECF5940, CD27-Alexafluor 700 (all from BD Biosciences); anti-V2-PC7, 
CD80-FITC, CD86-PE mAbs (all from Beckman Coulter) and anti-CD40-APC mAb 
(Miltenyi-Biotech). For in vitro analysis cells were labelled with anti-CD3-BV510, HLA-
DR-Alexafluor 700, HLA-ABC-V450 mAbs (all from BD Biosciences); anti-Vδβ-FITC, 
CD80-PC7, CD83-PE, CD86-APC Alexafluor 750 mAbs (all from Beckman Coulter) 
and anti-CD40-APC mAbs (Miltenyi-Biotech). FACS data were acquired using a LSR 
Fortessa 2-Blue 6-Violet 3-Red 5-Yelgr laser configuration, a CantoII 4-Blue 2-Violet 
2-Red laser configuration and a Canto 4-Blue 2-Red laser configuration (all BD 
Biosciences). Analysis was performed using Diva 8 (BD Biosciences) and FlowJo 
9.3.2 (Tristar) softwares. Total lymphocyte counts from patient blood samples were 
carried out by the immunology laboratory (Bordeaux University Hospital) using 
FC500 Beckman Coulter flow cytometers. 
Parasite Culture 
FCR3 P.falciparum parasites were cultured in type O+ red blood cells (RBCs) (EFS-
Aquitaine), in RPMI-1640 supplemented with 10% human serum, gentamicin, 
glutamine and hypoxanthine, as previously described [2, 19]. Infected red blood cell 
(iRBC) cultures were regularly tested for absence of Mycoplasma contamination. 
Parasitemia was assessed using hydroethidine staining, as described [20] or 
examination of Giemsa stained smears. Parasite cultures were synchronized by 
sorbitol and/or heparin treatment as described [21, 22]. Mid-stage to late schizonts 
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around 36 hours post infection (hpi), were purified by gel floatation on gelofusin [20]. 
Parasitemia after purification was >80%. Supernatant was produced as previously 
described [21]. For Alkaline Phosphatase treatment, supernatants were treated with 
0.015 U/μl shrimp alkaline phosphatase for γ0 min at γ7°C, as described [23]. 
In vitro stimulation of VȖ9Vδβ T-cells  
PBMCs from malaria-naive healthy donors (EFS-Aquitaine) were isolated from blood 
by Ficoll density gradient and cultured in complete medium (RPMI-1640, 
supplemented with glutamine, antibiotics, non-essential amino acids, sodium 
pyruvate (all from Gibco Life Technologies), and 10% of heat-inactivated fetal calf 
serum (PAA Laboratories)) supplemented with 100 IU/ml interleukin (IL)-2 
(Peprotech) in 24 well plates (Thermo Scientific). PBMCs (1.5x106 cells/ml) were 
stimulated with 5x106/ml iRBC or 10 nM HMBPP (Echelon Biosciences). uiRBCs 
(5x106/ml) or CM alone were used as respective negative controls for phenotyping 
assays. 100 IU/ml IL-2 and 25 ng/ml IL-15 (Peprotech) were added after 72 h of 
culture. After 12 days in culture, VȖ9Vδβ T-cell purity was assessed by flow 
cytometry. If total Vδβ+ T-cell purity was <90% cells were sorted as described below.  
 
Mixed lymphocyte reaction 
Monocytes from malaria-naive healthy donors’ PBMCs were depleted using CD14-
beads (Miltenyi-Biotech). The CD14-negative fraction was then labelled with either 
anti-Vδβ-FITC or anti-V9-PC5 antibody (Beckman Coulter) and anti-FITC or anti-PE 
beads (Miltenyi-Biotech). Labelled cells were filtrated through LS then MS columns 
(Miltenyi-Biotech) and used when purity was >95%. Freshly sorted VȖ9+ T-cells (105) 
were cultured with 104 autologous irradiated (50 Gy) monocytes as feeders and 
stimulated with either 105-2x105 iRBCs, 0.2-1 nM HMBPP or 50% v/v iRBC-
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supernatant in complete medium supplemented with 100 IU/ml IL-2. After 6 days, 
Vδβ purity and phenotype were checked and the cells were used as effectors in 
MLR. Total allogenic CD4+ and CD8+ T-cells were sorted based on expression of 
CD4/CD8. Naive CD4+ and CD8+ T-cells were sorted as CD45RA+, and CCR7+ to 
purities of >99.2% from PBMCs of healthy donors. Sorted cells were labelled with 5 
µM CFSE (Invitrogen) in PBS-5% FCS for 5 min, washed thoroughly and starved 1 h 
in complete medium at 37°C before being used as responder cells in MLR. CD4+ and 
CD8+ cells (2x105) were mixed with decreasing ratios of irradiated (1β Gy) VȖ9+ T-
cells cells, namely -1:10, 10:1, 100:1, 1000:1, in 96 well round bottom plates. 
CD4/CD8 T-cells alone were incubated with 4 µg/ml Staphylococcus Enterotoxin B 
(SEB, Sigma-Aldrich) and 40 IU/ml IL-2 or in complete medium alone. After 5 days, 
cells were labelled with DAPI, anti-CD3-BV510, anti-CD4-PC7 and anti-CD8-APC 
mAbs. The percentages of CFSElow CD4+ and CD8+ T-cells were assessed by flow 
cytometry. For measurement of intracellular cytokine expression, MLR cultures were 
stimulated with PMA/Ionomycin (10 ng/ml and 1 µM, both from Sigma). Brefeldin A 
(10 µg/ml, BioLegend) was added 1 h later. Following 5 h of stimulation, cells were 
processed for extracellular and intracellular staining using the eBioscience Fix/Perm 
Kit. Cultures were stained with anti-CD4-APC H7, CD8-PCy7, CD3-FITC, V9-PCy5 
and IFN-BV421 mAbs. 
M1 antigen presentation assay 
CD8 T-cells specific for M1p58-66 presented in an HLA-A2 background were 
generated using the influenza matrix M1 protein-derived M1p58-66 peptide 
(GILGFVFTL) as described [6, 24]. HLA-A2+ or HLA-A2− in vitro-stimulated VȖ9Vδβ 
T-cells (3x105) were incubated overnight with 0.01-1 µM M1 protein in a 96 well 
round bottom plate (Falcon) for loading. M1p58-66 (0.01µM) was identically loaded 
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for 1 h immediately prior to co-culture. Effector cells were washed and co-cultured 
with M1p58-66-specific CD8 T-cell responders (0.3x106) for 4.5 h in complete 
medium plus 1 µg/ml brefeldin A. PMA/Ionomycin were used as positive polyclonal 
control for CD8 T-cell activation. Cells were labelled with anti-CD3-APC, CD8-PC7 
mAbs (both from BD Biosciences), and anti-Vδβ-FITC mAb (Beckman Coulter), fixed 
with FACs lysis buffer and permeabilized using Perm2 (both from BD Biosciences), 
then labelled with anti-IFNȖ-PE mAb (BD Biosciences).  
Statistical analysis 
Statistical analysis were performed using Graph-Pad Prism as follows: non-
parametric Mann Whitney U-test for comparisons of unpaired populations; Wilcoxon 
signed rank test for pairwise day0 vs day7 comparisons; Friedman test with Dunn’s 
multi-comparison adjustment for pairwise comparisons;  2-way ANOVA test with 
Bonferroni correction for time-course comparisons. Differences were considered 
significant at P<0.05. 
 
RESULTS 
VȖ9Vδ2 T-cells in P.falciparum malaria patients show increased expression of 
APC markers compared to healthy and non-malaria febrile controls.  
We first compared the surface expression of APC-markers VȖ9Vδβ T-cells in blood 
obtained from P.falciparum-infected adult patients, healthy controls and patients 
presenting with fever for reasons other than malaria (Figure 1 and Supplementary 
Figure 1). Overall, we observed higher levels of HLA-DR and CD86 expression on 
Vδβ+ T-cells from malaria patients at admission compared to healthy and non-malaria 
febrile controls. Both non-malaria febrile controls and malaria patients had a 
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decreased CD40 expression on day 0 compared to healthy controls, although this 
was less pronounced in malaria patients. There were no significant differences in 
percentage of Vδβ+/CD3+ T-cells between the three groups (Figure 1A) and no CD80 
expression was observed. With regard to memory phenotype, malaria patients 
presented less Tnaive and more Temra Vδβ+ T-cells compared to both healthy and non-
malaria febrile controls (Figure 1B). Interestingly there was strong homogeneity 
between the febrile controls free of malaria infection, despite presenting with 
heterogeneous infectious events (Table 1). Despite limited statistical power due to 
the low number of patients for whom both D0 and D7 blood samples were available, 
there appears to be a trend for an increase in percentage of Vδβ T-cells (as 
previously documented), and a decrease in HLA-DR and CD86 expression, though 
not significant (Figure 1C), concomitant with parasite clearance. There was also an 
increase in the Tcm and a decrease in the Temra Vδβ+ T-cells subsets (Figure 1C).  
To assess the effect of different previous exposures to malaria, we stratified the 
malaria patients between those of sub-Saharan African origin who were migrant to 
France and visiting friends and relatives in their country of origin (VFR), travelers -
Caucasian- of European origin (TEO), and travelers -Caucasian- of European origin 
with a history of frequent travel to endemic regions (FTEO). The majority of the 
cohort patients were VFR (n=22) (Table 1). While there were no significant 
differences in APC- or memory-phenotype between the groups, the VFR group was 
the only group consistently significantly different from the healthy and febrile controls 
(Supplementary Figure 1B). There was no correlation between parasitemia and APC 
phenotype. However, our cohort contained one highly severe case with 19% RBC 
parasitemia upon admission (Table 1, Patient 11), who showed high expression of 
HLA-DR and CD86 on Vδβ+ T-cells and a predominant Tem phenotype, which all 
diminished post-parasite clearance (Figure 1C,D). Altogether, these data 
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demonstrate that VȖ9Vδβ T-cells presenting phenotypic features of APCs can be 
found in vivo in the blood of malaria patients.  
 
VȖ9Vδ2 T lymphocytes acquire an APC-like phenotype after in vitro stimulation 
by blood-stage P.falciparum parasites. 
To investigate whether P.falciparum can induce APC maturation of VȖ9Vδβ T-cells, 
PBMCs from malaria naive, afebrile healthy donors were stimulated with intact 
5x106/ml iRBC. The synthetic phosphoantigen HMBPP was used as a positive 
control, 5x106/ml uninfected RBC (uiRBC) and complete medium were used as 
negative controls respectively (Figure 2). We found that iRBC stimulation significantly 
increased expression of all APC-associated markers tested over a 12-day culture 
period, though with different kinetics (Figure 2A, Supplementary Figure 2). iRBC 
induced a lower magnitude of expression than HMBPP. Expression of all APC 
markers was induced in the negative controls, but to lower/marginal levels, and with 
delayed kinetics. This was likely due to the presence of IL-2 and IL-15 in the culture 
medium, indicating that APC-like phenotype acquisition is not solely dependent on 
TCR signaling.  
These results indicate that P.falciparum can promote in vitro the expression of an 
APC phenotype by VȖ9Vδβ T-cells.  
 
VȖ9Vδ2 T lymphocytes acquire APC-like functions after in vitro stimulation by 
blood-stage P.falciparum parasites. 
One of the hallmarks of APCs is the ability to stimulate allogenic αȕ T-cells. We thus 
tested the capacity of peripheral-blood isolated VȖ9Vδβ T-cells stimulated in vitro 
with P.falciparum to activate CD4+ and CD8+ αȕ T-cells in a mixed lymphocyte 
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reaction (MLR). VȖ9Vδβ T-cells stimulated by intact iRBCs induced proliferation of 
total allogenic CD4+ and CD8+ T-cells (Figure 3A). Moreover, VȖ9Vδβ T-cells 
stimulated with iRBC culture supernatant induced both proliferation (Figure 3B) and 
cytokine production (Figure 3C) by allogenic naive CD4+ and CD8+ T-cells, 
demonstrating genuine professional APC activity. Indeed, naive  T-cell activation 
was not observed with unstimulated VȖ9Vδβ T-cells (Figure 3B). Much lower activity 
was observed when using the uiRBC culture supernatant and alkaline phosphatase-
treated iRBC culture supernatant. This is in agreement with the susceptibility of 
parasite-derived phosphoantigens to dephosphorylation, and rules out the 
requirement of unrelated parasite or RBC molecules for the induction of APC 
features in VȖ9Vδβ T-cells. 
It has been documented that isopentenylpyrophosphate- or HMBPP-stimulated 
VȖ9Vδβ T-cells can efficiently cross-present exogenous antigens to CD8+ T-cells [6, 
24]. To assess whether P.falciparum-stimulated VȖ9Vδβ T-cells have the same 
ability, we used an antigen presentation assay based upon the processing and 
presentation of the Influenza virus M1 antigen to M1p58-66-specific CD8+ T-cells in a 
HLA-A2 background (Figure 4). We found that P.falciparum-stimulated, M1 protein-
loaded, VȖ9Vδβ T-cells activated the M1p58-66-specific CD8+ T-cell responder line 
as efficiently as HMBPP-stimulated VȖ9Vδβ T-cells (Figure 4B). This activation was 
dependent on both M1 protein loading and HLA-Aβ expression by the VȖ9Vδβ T-
cells, demonstrating that activation was due to M1 protein up-take, processing and 
cross-presentation of the M1p58-66 epitope.  
Taken together, our results show that P.falciparum-stimulated VȖ9Vδβ T-cells readily 
acquire the potential to act as professional APCs and induce responses by CD4+ and 
CD8+ T-cells. 
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DISCUSSION  
Protective immunity to malaria infection in endemic areas is acquired slowly over 
many years of exposure and is not stable. There are many explanations for this 
including P.falciparum antigenic diversity, T-cell inhibition and B-cell modulation in 
infected individuals (reviewed [25]). In addition, parasites have evolved mechanisms 
to inhibit the antigen presenting machinery. There is both in vitro and ex vivo 
evidence that iRBC inhibit effective DC maturation and function [11-15]. Our current 
results indicate that VȖ9Vδβ T-cells, which are efficiently activated in vivo during 
P.falciparum infection, could thus represent an alternative route for antigen 
presentation to αȕ T-cells in the context of malaria. We show that in vivo-stimulated 
VȖ9Vδβ T-cells from malaria patients display a membrane phenotype associated with 
conventional APCs, which is not observed in the febrile non-malaria infected controls. 
The size increase and stability of the peripheral-blood memory subpopulations 
indicate that, although the patients were lymphopenic, malaria didn’t damage the 
blood central memory compartment as reported for HIV infections [26]. From our 
malaria patient sub-grouping, it appears that originating from a malaria endemic area 
correlates with a higher ex-vivo VȖ9Vδβ T-cell APC-phenotype upon infection. 
Previous studies have shown that Vδ1+, not Vδβ+ T-cells are expanded in the 
peripheral blood of malaria patients from endemic regions [27]. Our data may 
possibly reflect a situation where Vδβ+ T-cells take on an APC phenotype once their 
inflammatory functions are downregulated. VȖ9Vδβ T-cells express the chemokine 
CCR7 after phosphoantigen stimulation in vitro [28], thus their absence from 
peripheral blood could be due to their migration to lymphoid organs. However, as the 
sample size of the TEO and FTEO groups was small (n=4 in each group), this 
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interpretation needs to be further substantiated. Further, we cannot rule out a genetic 
effect in patients of different ethnic backgrounds in the VFR and TEO/FTEO groups. 
Systematic information on previous malaria infection(s), the duration of residence of 
VFR in both their native country or in France, and the frequency of visits to endemic 
regions in the VFR and FTEO groups were not available. In this study, we focused on 
samples taken pre-treatment, resulting in mainly recruiting non- and mildly-severe 
malaria cases. This may have led to underestimating the average level of VȖ9Vδβ T-
cells displaying an APC phenotype in malaria patients, given that the strongest APC 
phenotype was seen in our unique extremely severe malaria patient. From this 
severe hyperparasitemic case, it is clear that high HLA-DR and CD86 expression can 
occur in VȖ9Vδβ T-cells during acute malarial infection. The dramatic decrease of 
both HLA-DR and CD86 expression by day 7, after patient recovery, further indicates 
that this APC-like phenotype was transient in blood and associated with acute 
infection. 
Little in vivo evidence of APC-like phenotype and functions of Ȗδ T-cells have been 
documented. In mice, where a VȖ9Vδβ T-cell equivalent population has yet to be 
found, Frossard et al. describ d the APC-like phenotype of Ȗδ T-cells induced in vivo 
by cholera toxin, and their role in the modulation of oral tolerance in food allergy 
pathogenesis [29]. More recently, Wan et al. described Ȗδ T-cells with APC-like 
capabilities in zebrafish [30]. Thus, this work presents the first evidence to our 
knowledge of VȖ9Vδβ T-cell APC-like differentiation occurring physiologically in 
humans, in a pathological situation.  
The presence of VȖ9Vδβ T-cells with an APC-like phenotype in malaria patients is 
supported by our demonstration that in vitro iRBC stimulated VȖ9Vδβ T-cells readily 
express both presenting and co-stimulatory molecules associated with APCs. As a 
confirmation of the functional relevance of these findings, we showed that iRBC-
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stimulated VȖ9Vδβ T-cells can take up, process and cross-present exogenous M1 
protein to M1p58-66-specific CD8 T-cells as effectively as in vitro HMBPP-stimulated 
VȖ9Vδβ T-cells. P.falciparum-stimulated VȖ9Vδβ T-cells were also capable of 
activating naive allogenic αȕ T-cells, as shown by our MLR experiments. In this 
model, we observed some activation of  T-cells by VȖ9Vδβ T-cells cultured with 
uiRBC supernatant, consistent with the induction of a small proportion of APC 
VȖ9Vδβ T-cells in this condition (Figure 2) that is probably due to the presence of IL-
2 and IL-15 in the culture medium. HMBPP stimulation consistently induced 
increased expansion and APC-marker expression in VȖ9Vδβ T-cells compared to 
iRBC stimulation. This could be due to lower phosphoantigen levels with iRBC 
stimulation (5x106/ml iRBC equates to ~1 nM HMBPP [31]), but we cannot rule out 
the presence of some iRBC-derived inhibitor mitigating the activation. iRBC released 
molecules such as hemozoin have been shown to inhibit DC maturation [13]. 
However, if similar inhibition occurs for the VȖ9Vδβ T-cells, it does not overtake their 
activation by phosphoantigens. CD36-dependent iRBC adhesion has also been 
proposed to mediate DC inhibition [15]. The FCR3 parasite strain used in our assays 
was non-adherent, therefore CD36-mediated inhibition would not occur in our 
experimental system. As CDγ6 expression of VȖ9Vδβ T-cells post zoledronate 
stimulation has been documented [32], it will be important to assess VȖ9Vδβ T APC-
like maturation after co-culture with CD36-binding iRBCs. Recent data on 
Mycobacteria immunity [33] showed that APC functions of VȖ9Vδβ T-cells do not 
require soluble mediators and involve cell-to-cell contact. In our hands, both intact 
iRBC and soluble products from P.falciparum were able to stimulate VȖ9Vδβ T-cells. 
Moreover, the abrogation of such stimulation after phosphatase treatment of the 
supernatants indicates that soluble phosphorylated mediators are necessary to 
A
cc
ep
te
d 
M
an
us
cr
ip
t
Howard et al., Manuscript        MS#61644 
16 
 
induce APC-like functions. Thus, it is likely M. tuberculosis and P.falciparum differ in 
their mechanisms of APC induction in VȖ9Vδβ T-cells.  
Magnitudes and kinetics of APC-marker stimulation differ in the publications 
mentioned above [29, 30, 32, 33], suggesting that in vitro culture conditions can 
modulate VȖ9Vδβ T-APC maturation kinetics. Under the stimulatory conditions we 
used, there appears to be two patterns of expression at least within the timeframe of 
our observation, with first transient expression of CD40 and CD83 alongside 
increased HLA class I expression and later on stable expression of HLA-DR, 
alongside expression of CD80 and CD86. Though peak expression points didn’t 
coincide for the two types of phenotype, expression of all markers was above base-
line between days 6 and 9 when VȖ9Vδβ T-cells were stimulated among the PBMCs 
and between days 3 and 6 when they were purified before stimulation. In the latter 
situation, the pattern was sufficient to induce allogenic  T-cell stimulation. From our 
kinetics data, one can surmise that in vivo the VȖ9Vδβ T-APCs have matured 
sufficiently after 3-5 days of iRBC exposure. Based on their parasitemia at 
admission, the patients have experienced on average 3-5 replication cycles, i.e ~6-10 
days of blood-stage infection. Thus, the reduced CD40 and high HLA-DR and CD86 
levels in patients VȖ9Vδβ T-cells correlate with the kinetics of expression observed in 
our cultured lines. It will be important to assess the functional ability of in vivo iRBC-
induced VȖ9Vδβ T-APC-like cells. Our study design did not allow investigating this 
point, which requires to collect from patients much larger volumes of blood. 
Taken together, our present study proposes a novel role for human VȖ9Vδβ T-cells in 
malaria-infected patients, promoting initiation of the adaptive response despite a 
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LEGENDS TO THE FIGURES 
Figure 1. VȖ9Vδβ T lymphocytes from P.falciparum malaria patients show 
increased expression of presenting and co-stimulatory molecules compared to 
healthy and non-malaria febrile infected controls. VȖ9Vδβ T lymphocytes from 
P.falciparum-infected patients collected at admission pre-treatment were assessed 
for both APC and memory phenotypes. Patients with non-malaria febrile symptoms, 
and non-malaria exposed healthy donors were used as controls. % of (A) HLA-DR, 
CD40 and CD86+/Vδ2+ T-cells and (B) Tnaive, Tcm, Tem and Temra Vδ2+ T-cells in whole 
blood from healthy controls (n=11), febrile controls (n=6) and malaria patients at the 
time of hospital admission (n=27). Each point represents an individual patient. The 
mean is indicated by the horizontal bar. Data were analysed using Mann Whitney U 
test for unpaired samples (**P<0.01, *P<0.05). (C) % of HLA-DR, CD40, CD86+/Vδ2+ 
T-cells (left panel) and % Tnaive, Tcm, Tem and Temra Vδ2+ T-cells (right panel) in the 5 
patients from whom paired blood samples on the day of admission (D0) and on day 7 
post-treatment (D7)  were obtained. The trends observed were non significant as 
calculated by a Wilcoxon signed rank tests for matched pairs. (D) Histograms 
(Unstained control in grey) at D0 and % of APC and memory phenotype of Vδ2+ T-
cells on D0 and D7 in whole blood of a severe malaria case (patient#11) presenting 
with 19% parasitemia at admission. 
 
Figure β. VȖ9Vδβ T lymphocytes acquire an APC-like phenotype after in vitro 
stimulation by P.falciparum blood-stage parasites. Kinetics of Vδ2+ T-cell 
expansion and HLA-DR, CD80, CD86, CD83 and CD40 expression on Vδβ+ T-cells 
stimulated 12 days with 5 x106/ml iRBC (red), 5x106/ml uiRBC (blue), 10nM HMBPP 
(green) or complete medium (black). (A) Representative donor and (B) Mean of 5 
donors. Expressed % positive Vδ2+ T-cells. The mean is indicated by the horizontal 
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bar. Statistical significance was calculated using 2-way ANOVA with Bonferroni 
correction, with comparing at each time point the values for % of marker expression 
in (uiRBC – iRBC) (***P<0.001, **P<0.01, *P<0.05).  
 
Figure 3. P.falciparum-stimulated VȖ9Vδβ T-cells are able to induce αȕ T 
lymphocyte allogenic stimulation. Freshly isolated VȖ9Vδβ T-cells were stimulated 
for 6 days and mixed with allogenic CD4+ (left) and CD8+ (right) T-cells. Proliferation 
was assessed at day 5 as % of CFSE low in (A) total αȕ CD4+ and CD8+ T-cells co-
cultured with VȖ9Vδβ T-cells stimulated with 0,2-1 nM HMBPP or 1-2x106 intact 
iRBC/ml or (B) naive αȕ CD4+ and CD8+ T-cells co-cultured with (black circles) either 
fresh unstimulated VȖ9Vδβ T-cells (unstim) or VȖ9Vδβ T-cells stimulated with 50% 
v/v supernatants (SN) of iRBC or uiRBC, or cultured with phosphatase alkaline-
treated iRBC supernatants (iRBC-SN+AP). (C) Intr cellular IFNȖ expression by αȕ T-
cells was measured after the first 5 h of co-culture shown in B. αȕ T-cells alone non-
stimulated (ns) or stimulated with Staphylococcus Enterotoxine B (SEB) were used 
as negative and positive controls respectively (grey circles). Mean ±SD of three 
independent experiments. Data were analyzed using a Friedman test with Dunn’s 
multi-comparison correction. In A, global analysis was performed excluding SEB 
condition used as positive control for T-cell proliferation (***P<0.001, **P<0.01, 
*P<0.05).  
 
Figure 4. iRBC-stimulated VȖ9Vδβ T-cells are able to cross present an M1 
derived antigen to specific CD8+ αȕ T lymphocytes. HLA-A2-positive and -
negative VȖ9Vδβ T-cell lines generated by stimulation for 12 days with 5x106 
iRBC/ml (black bars) or 10 nM HMBPP (white bars), sorted by positive selection and 
loaded overnight with M1 protein, or loaded 1 h with 0.01 µM M1pp58-66. VȖ9Vδ2 T-
A
cc
ep
te
d 
M
an
us
cr
ip
t
Howard et al., Manuscript        MS#61644 
23 
 
cells were then washed thoroughly and co-cultured with M1pp58-66 specific CD8 T-
cells and the IFNȖ production by the CD8 T-cells measured. (A) Gating strategy for 
IFNȖ+ CD8+ T-cell identification. Unstimulated control in grey histogram. (B) 
Intracellular IFNȖ expression by CD8+ αȕ T-cells. CD8+ αȕ T-cells alone, non-
stimulated (ns) or stimulated with PMA/ionomycin (P/I) were used as negative and 
positive controls, respectively (grey bars). Mean ±SEM of two independent 
experiments with n=3 for HLA-A2+ and n=2 for HLA-A2- VȖ9Vδβ T-cells.  
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Table 1: Patient cohort information. 
Patient Febrile Infection Parasite-
mia Details 
Duration of stay in 
malaria endemic zone Group Disease attributes 
Anti-infection specific 
treatment after sampling 
P1 Febrile, non-malarial NA 
 
ND FC 
  P2 Dengue fever NA Non-migrant ND FC Non-complicated Unknown 
P3 
E Coli urinary 
infection (compatible 
with pyelonephritis) 
NA Non-migrant ND FC Non-complicated /  RAS Ceftriaxone 
P4 
Prostatitis - Klebsiella 
pneumonia BLSE + 
Lambliasis (fortuitous 
discovery)  
NA Migrant,  from the Congo ND FC 
Acute kidney 
dysfunction with urinary 
retention. 
Ceftriaxone, then ertapenem 
then sulfamethoxazole and 
trimethoprim 
(bactrim)+albendazole 
P5 
EBV infection 
(compatible with 
infectious 
mononucleosis) 
NA Migrant, regularly travel to Tchad. ND FC 
Non-complicated /  
RAS Unknown 
P6 Undocumented viral 
infection NA Migrant, from Cameroon 3 weeks FC  Sampled before treatment 
P7 P. falciparum 0.5 Non migrant 2 weeks humanitarian mission. FTEO Non-complicated 
DHA-PQP + metronidazole 
(blastocytis hominis in feces) 
P8 P. falciparum 0.6 Non-migrant, previous 
malaria episodes. 
2 months 
in Ivory Coast FTEO 
Non-complicated /  
high platelets DHA-PQP 
P9 P. falciparum 3 Military. 5 months 
military mission FTEO Non-complicated DHA-PQP 
P10 P. falciparum 4.4 Non-migrant, previous 
malaria cases. 
7 months  
humanitarian mission FTEO Non-complicated DHA-PQP 
P11 P. falciparum 19 Non-migrant, frequent  trips to the Ivory Coast. 2 weeks FTEO 
Severe: 
hyperparasitemia, 
prostration, instability, 
hemodynamic. 
Artesunate then DHA-PQP + 
ceftriaxone 
P12 P. falciparum <0,01 Not specified ND TEO   
P13 P. falciparum 0.05 Not specified 2 weeks TEO Non-complicated Atovaquone/proguanil 
P14 P. falciparum 0.5 Non-migrant  TEO Non-complicated DHA-PQP 
P15 P. falciparum 2.23 Non-migrant 1 month TEO Non-complicated DHA-PQP 
P16 P. spp 0 (PCR+) Migrant, born in the Ivory Coast. Internship VFR Non-complicated Atovaquone/proguanil 
P17 P. falciparum <0,01 Migrant, from the Ivory Coast. 5 weeks VFR Non-complicated 
DHA-PQP then 
atovaquone/proguanil 
P18 P. falciparum 0.02 Migrant, of many years. Expatriate VFR Non-complicated DHA-PQP 
P19 P. falciparum 0.02 
Migrant, resident many years 
in Equatorial Guinea and 
Cameroon. 
2 weeks VFR Non-complicated DHA-PQP 
P20 P. falciparum 0.06 Migrant, resident many years in Gabon. 2 weeks VFR Non-complicated DHA-PQP 
P21 P. falicparum 0.14 Migrant,  from Cameroon. 1 month VFR Non-complicated 
DHA-PQP. Already treated 
quinine three days in 
Cameroon. Possible 
resistant parasite. 
P22 P. falciparum 0.2 Migrant, from Cameroon. 3 months VFR Non-complicated DHA-PQP 
P23* P. falciparum 0.3 Migrant, originally from the Ivory Coast.  VFR Non-complicated DHA-PQP 
P24 P. falciparum 0.5 Migrant,  from the Congo. 3 months VFR 
Non-complicated / 
supplementary 
conjunctivitis  
DHA-PQP 
P25* P. falciparum 0.6 Migrant, from Congo. ND VFR Non-complicated DHA-PQP 
P26 P. falciparum 1.1 Migrant, from Cameroon. 15 days VFR Non-complicated  DHA-PQP 
P27 P. falciparum 1.44 Migrant,  from Ivory Coast 2 months VFR Non-complicated 
Atovaquone/proguanil 
(anomaly ecg - no DHA-
PQP) 
P28 P. falciparum 1.6 
Migrant, born in Cameroon, 
multiple malaria cases in 
childhood. 
10 days VFR Non-complicated DHA-PQP 
P29 P. falciparum 1.6 Migrant, lived long time in Ivory coast. 1 week VFR Non-complicated DHA-PQP 
P30 P. falciparum 3 Resident Cameroon, in France for work/tourism. Resident VFR Sever: prostration DHA-PQP 
P31 P. falciparum 4.5 Migrant, from Cameroon, 
resident 7 years. 
Expatriate (resident  
2 years Douala) VFR Sever: jaundice DHA-PQP 
P32 P. falciparum 5 Migrant, from Angola 2 month VFR Sever: parasitemia 5% DHA-PQP 
P33 P. falciparum 5.5 Migrant, from Cameroon 1 month VFR Sever: parasitemia 5,5% DHA-PQP 
P34* P. falciparum 6 Migrant, from Cameroon. 1.5 months Cameroon VFR Severe: parasitemia 6% DHA-PQP 
P35 P. falciparum 2 Migrant, from Senegal. 6 months, Senegal VFR Non-complicated DHA-PQP 
P36 
P. falciparum 
+ P. malariae (PCR 
only, not seen on 
blood smear) 
0.85 Migrant 4 months Senegal VFR Non-complicated DHA-PQP 
P37 P. falciparum 0.04 Migrant, from Ivory Coast 4 weeks, Ivory Coast VFR Non-complicated DHA-PQP 
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Abbreviations: ND: unknown; NA : non-applicable; P: Plasmodium ; EBV: Epstein-Barr virus; E: Escherichia ; DHA-PQP : dihydroartemisinin-
piperaquine; FC : febrile controls; VFR : malaria patients migrants to France born in malaria endemic countries and visiting friends and 
relatives in malaria endemic areas; TEO : malaria patients, travellers of European (Caucasian) origin; FTEO : malaria patient, travellers of 
European (Caucasian) origin with a history of frequent visits to endemic areas; Migrant: migrant to France; Non-migrant: born and resident in 
France. *Insufficient (<β00) VȖ9Vδβ T-cell events recorded therefore patient not included in Figure 1 analysis. 
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